Navigation Links
Seahorse Bioscience Appoints Former Molecular Devices Executive Dr. Joseph D. Keegan to Board of Directors
Date:12/20/2007

New Board Member Brings Life Sciences Tools Experience to the Leader in

Cellular Bioenergetic Profiling

N. BILLERICA, Mass., Aug. 10 /PRNewswire/ -- Seahorse Bioscience, the leading provider of tools for real-time measurement of cellular bioenergetics in microplates, announced today that former Molecular Devices executive Joseph Keegan has been appointed to the company's Board of Directors. In this position, Keegan will apply his successful business experience in the life sciences industry to accelerate the growth of Seahorse Bioscience's novel technology for profiling cell metabolism.

"As the company moves into its next phase of growth, it will require a strong understanding of this market," said Jay Teich, Seahorse Bioscience's CEO. "Joe's tremendous success in building Molecular Devices, combined with his extensive labware experience makes him an ideal addition to our Board."

Keegan brings more than 25 years of experience managing life science tools businesses. As CEO of Molecular Devices, he developed a strategy combining internal growth with acquisitions to build the dominant supplier of detection solutions for drug discovery, clinical and research applications. Keegan joined MDC from Becton Dickinson and Company where he served as President of Worldwide Tissue Culture. Prior to Becton Dickinson, Keegan was Vice President of Microscopy and Scientific Instruments Division of Leica, Inc.

"Seahorse has developed a 'stethoscope for living cells.' The ability to measure cell metabolism in a truly non-invasive way has very broad applications," said Keegan. "Drawing on my experience with both instrument and labware businesses, I look forward to helping Seahorse grow a successful business in a field that I understand very well."

About Seahorse Bioscience

Seahorse Bioscience is changing cancer, obesity and diabetes drug discovery programs the world over. Seahorse headquarters are located in North Billerica, Massachusetts. For more information, please visit http://www.seahorsebio.com.

Media Contact:

Cheryle Cushion

Seahorse Bioscience

(978) 671-1697

ccushion@seahorsebio.com


'/>"/>
SOURCE Seahorse Bioscience
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
2. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
3. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
4. Ohio Ranks Best in the Midwest for Venture Capital Investment in Health Care Bioscience Industry
5. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
6. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
7. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
8. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
9. Todd R. Nelson Named Chief Executive Officer of eBioscience, Inc.
10. Magellan Biosciences Names Steven E. Diamond, PhD, Chief Scientific Officer
11. Pressure BioSciences, Inc. Issued First Patent in Canada
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2016)... (PRWEB) , ... May 20, 2016 , ... Korean researchers ... that it may offer a new way to treat the disease. Surviving Mesothelioma has ... now. , Scientists from several Korean institutions based their mesothelioma study on the ...
(Date:5/19/2016)... Ashland, Virginia (PRWEB) , ... May 19, 2016 , ... ... a new 30,000 square foot office building is complete. The new structure adds a ... In 2011, Anton Paar USA purchased 2.4 acres of land, along with ...
(Date:5/19/2016)... -- There is no saying when exactly ... pressures in pricing and lack in consumer confidence. One ... - numerous opportunities are up for grabs but this ... four names in this sector: Portola Pharmaceuticals Inc. (NASDAQ: ... VTAE ), Anthera Pharmaceuticals Inc. (NASDAQ: ...
(Date:5/19/2016)... May 19, 2016 ... (OTC PINK: RGBPP) announced today initiation of a ... cord blood based cancer immunotherapeutic product leveraging its ... Regen described a generation of cord blood derived ... gene silencing.  The product in development will be ...
Breaking Biology Technology:
(Date:3/15/2016)... -- Yissum Research Development Company of the Hebrew ... Hebrew University, announced today the formation of Neteera ... human biological indicators. Neteera Technologies has completed its first ... ... emissions from sweat ducts, enables reliable and speedy biometric ...
(Date:3/10/2016)... India , March 10, 2016 ... a new market research report "Identity and Access Management ... & Audit, Compliance, and Governance), by Organization Size, by ... to 2020", published by MarketsandMarkets, The market is estimated ... USD 12.78 Billion by 2020, at a Compound Annual ...
(Date:3/8/2016)... , March 8, 2016   Valencell ... technology, today announced it has secured $11M in ... GII Tech, a new venture fund being launched ... additional participation from existing investors TDF Ventures and ... funds to continue its triple-digit growth and accelerate ...
Breaking Biology News(10 mins):